Baseline patient and procedural characteristics
| Characteristic | All n=200 | Secret n=100 | Control n=100 | P value |
| Baseline patient characteristics | ||||
| Age, years | 68±9.9 | 68±10.4 | 68±9.4 | 0.99 |
| Male | 147 (73.5) | 76 (76.0) | 71 (71.0) | 0.42 |
| Smoker | 41 (20.5) | 21 (21.0) | 20 (20.0) | 0.86 |
| Hypertension | 105 (52.5) | 46 (46.0) | 59 (59.0) | 0.07 |
| Diabetes mellitus 2 | 39 (19.5) | 14 (14.0) | 25 (25.0) | 0.05 |
| Dyslipidaemia | 109 (54.5) | 47 (47.0) | 62 (62.0) | 0.03 |
| BMI, kg/m2 | 28 (25–30) | 27 (25–30) | 28 (25–30) | 0.98 |
| Believes in “The Secret” | 150 (75.0) | 73 (73.0) | 77 (77.0) | 0.51 |
| Preprocedural medication | ||||
| Aspirin | 102 (51.0) | 53 (53.0) | 49 (49.0) | 0.57 |
| Clopidogrel | 6 (3.0) | 2 (2.0) | 4 (4.0) | 0.41 |
| Anticoagulation | 17 (8.5) | 6 (6) | 11 (11) | 0.21 |
| AVK | 4 (2.0) | 0 (0.0) | 4 (4.0) | 0.12 |
| DOAC | 13 (6.5) | 6 (6.0) | 7 (7.0) | 0.77 |
| DAPT | 43 (21.5) | 20 (20.0) | 23 (23.0) | 0.49 |
| Aspirin + clopidogrel | 8 (4.0) | 3 (3) | 5 (5) | 0.72 |
| Aspirin + prasugrel | 35 (17.5) | 17 (17.0) | 18 (18.0) | 0.85 |
| Aspirin + DOAC | 3 (1.5) | 2 (2.0) | 1 (1.0) | 1.00 |
| Clopidogrel + DOAC | 1 (0.5) | 0 (0.0) | 1 (1.0) | 1.00 |
| None | 28 (16.0) | 17 (17.0) | 11 (11.0) | 0.22 |
| HBR-ARC bleeding risk | ||||
| HBR-ARC major criterion | 45 (22.5) | 20 (20.0) | 25 (25.0) | 0.40 |
| HBR-ARC minor criterion | 45 (22.5) | 20 (20.0) | 25 (25.0) | 0.40 |
| Creatinine, µM/L | 79 (67–91) | 77 (68–90) | 81 (66–91) | 0.73 |
| CKD-EPI, mL/min | 81 (69–92) | 81 (69–91) | 82 (69–92) | 0.95 |
| Haemoglobin, g/dL | 14 (13–15) | 14 (13–15) | 14 (13–15) | 0.14 |
| Thrombocytopenia (<100×109/L) | 3 (1.5) | 0 (0.0) | 3 (3.0) | 0.08 |
| Treatment for a cancer <12 months | 7 (3.5) | 3 (3.0) | 4 (4.0) | 0.70 |
| Chronic bleeding | 5 (2.5) | 3 (3.0) | 2 (2.0) | 0.65 |
| Procedure | ||||
| Vessels diseased | ||||
| 0-vessel | 112 (56.0) | 58 (58) | 54 (54) | 0.57 |
| 1-vessel | 58 (29.0) | 26 (26.0) | 32 (32.0) | 0.35 |
| 2-vessel | 24 (12.0) | 12 (12.0) | 12 (12.0) | 1.00 |
| 3-vessel | 6 (3.0) | 2 (2.0) | 4 (4.0) | 0.68 |
| Lesions, n | 0 (0–1) | 0 (0–2) | 0 (0–1) | 0.86 |
| Vascular access | ||||
| Radial | 115 (57.5) | 51 (51.0) | 64 (64.0) | 0.06 |
| Femoral | 76 (38.0) | 44 (44.0) | 32 (32.0) | 0.08 |
| Mixed | 9 (4.5) | 5 (5.0) | 4 (4.0) | 1.00 |
| 6 F sheath | 189 (94.5) | 95 (95.0) | 94 (94.0) | 0.94 |
| Procedure with stent implantation | 87 (43.5) | 42 (42.0) | 45 (45.0) | 0.66 |
| Stents by procedure, n | 2 (1–2) | 2 (1–2) | 1 (1–2) | 0.05 |
| Duration, min | 23 (11–40) | 25 (11–41) | 21 (11–37) | 0.83 |
| Procedural medication | ||||
| Aspirin | 6 (3.0) | 1 (1.0) | 5 (5.0) | 0.21 |
| Heparin | 125 (62.5) | 64 (64.0) | 61 (61.0) | 0.66 |
| Aspirin + heparin | 24 (12.0) | 7 (7.0) | 17 (17.0) | 0.03 |
| Aspirin + heparin + tirofiban | 1 (0.5) | 1 (1.0) | 0 (0.0) | 1.00 |
| None | 44 (22.0) | 27 (27.0) | 17 (17.0) | 0.09 |
| Given postprocedural medication | ||||
| P2Y12 inhibitor | 78 (39.0) | 37 (37.0) | 41 (41.0) | 0.97 |
| Clopidogrel | 28 (14.0) | 8 (8.0) | 20 (20.0) | 0.01 |
| Prasugrel | 50 (25.0) | 29 (29.0) | 21 (21.0) | 0.19 |
| Protamine | 1 (0.5) | 1 (1.0) | 0 (0.0) | 1.00 |
| None | 121 (60.5) | 62 (62.0) | 59 (59.0) | 0.66 |
| Bleeding outcomes | ||||
| Bleeding BARC ≥1 at discharge | 55 (27.5) | 28 (28) | 27 (27) | 0.85 |
| BARC 1 | 30 (15.0) | 16 (16.0) | 14 (14.0) | 0.69 |
| BARC 2 | 25 (12.5) | 12 (12.0) | 13 (13.0) | 0.81 |
Continuous variables are expressed as mean±SD, median [Q1-Q3]; categorical variables are expressed as absolute and relative frequencies.
AVK, vitamin K antagonist; BARC, Bleeding Academic Research Consortium; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulants; HBR, high bleeding risk.